Biodesix, Inc.

Oct 22, 2026

Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026

Biodesix, Inc. announced it will release its financial results for Q3 2026 on November 5. The company will host a conference call at 4:30 p.m. ET to discuss these results and provide a business update. Interested parties can register for the webcast and participate in a Q&A session.

Oct 19, 2026

American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification

The American College of Chest Physicians has published a new framework for lung nodule programs, emphasizing the integration of biomarker testing for better risk stratification. Developed by a multidisciplinary panel, the framework aims to standardize clinical practices and improve patient outcomes. Dr. Sonali Sethi highlighted its importance in accelerating care and enhancing diagnostic confidence.

Oct 19, 2026

Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers

Biodesix has announced the addition of Digital Diagnostics to its Lung Diagnostics strategy, creating a multimodal platform that integrates blood-based and imaging biomarkers. The first product, a radiomics-based test for lung nodule risk assessment, is being developed in collaboration with Vanderbilt University and is expected to be commercially available by 2028. Initial performance data will be presented at the RSNA Annual Meeting in December 2026.

Oct 13, 2026

Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026

Biodesix, Inc. announced multiple presentations at CHEST 2026 showcasing the integration of Nodify Lung testing into lung nodule management. The presentations include new analyses from the CLARIFY study, emphasizing the clinical value of blood-based biomarkers. The focus is on how these tests can enhance decision-making and patient adherence to follow-up care.

Sep 24, 2026

Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

Biodesix has announced progress in two Molecular Residual Disease (MRD) monitoring programs, one tumor-informed and one tumor-naïve. These solutions utilize circulating tumor DNA (ctDNA) to assess disease status post-treatment. Collaborations with Bio-Rad and Thermo Fisher aim to enhance testing sensitivity and accessibility, marking a strategic expansion into precision oncology.

Sep 14, 2026

Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings

Biodesix's VP of Quality and Regulatory Affairs, Brianna Phillips, will present at the RAPS and SOCRA Annual Meetings. Her leadership has established Biodesix Labs as a leader in diagnostics with multiple accreditations. The company’s quality and regulatory processes have significantly improved patient care for lung disease diagnostics, impacting over 100,000 patients.

Sep 3, 2026

Biodesix to Participate in Upcoming Investor Conferences

Biodesix, Inc. will participate in three upcoming investor conferences in New York, including the Lake Street Capital Markets' 10th Annual Best Ideas Growth Conference and the H.C. Wainwright 28th Annual Global Investment Conference. Additionally, Biodesix will present a panel discussion on MRD monitoring in solid tumors at the Roth Healthcare Opportunities Conference. These events underscore Biodesix's commitment to advancing diagnostic solutions.

Aug 5, 2026

Biodesix Announces Second Quarter 2026 Results and Highlights

Biodesix, Inc. reported strong financial results for Q2 2026, with total revenue reaching $26.9 million, marking a 34% increase year-over-year. The company achieved an 82% gross margin and noted significant growth in Diagnostic Testing revenue, which rose by 42%. Despite a net loss of $7.3 million, Biodesix remains optimistic about its growth trajectory and maintains its revenue guidance for the full year.

Aug 4, 2026

Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference

Biodesix, Inc. will participate in Canaccord Genuity's 46th Annual Growth Conference on August 11-12, 2026. The leadership team will present in a fireside chat and conduct in-person investor meetings. The presentation will be available for live webcast and replay on the company's website, highlighting its diagnostic solutions.

Jul 22, 2026

Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026

Biodesix, Inc. announced it will release its second quarter financial results on August 5, 2026. The company will hold a conference call and webcast at 4:30 p.m. Eastern Time to discuss these results and provide a business update. Interested parties can register for the webcast and participate in a Q&A session.

May 11, 2026

▲ +5.2%on this news

Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy

Biodesix, Inc. announced that it will present real-world clinical and economic data related to its Nodify Lung testing at the ATS Annual Meeting from May 15-20, 2026. The presentations aim to demonstrate the value of blood-based testing in lung cancer detection and management. CEO Scott Hutton emphasized the importance of these tests in enhancing patient care and outcomes.

May 4, 2026

Biodesix Announces First Quarter 2026 Results and Highlights

Biodesix, Inc. reported strong financial results for the first quarter of 2026, achieving $25.6 million in revenue, a 42% increase compared to the same period in the previous year. The company also reported a gross margin of 84% and has raised its revenue guidance for the full year to a range of $108 to $114 million, reflecting a projected growth of approximately 25%. Significant growth was seen in both the Diagnostic Testing and Development Services segments, with the latter's revenue doubling year-over-year. However, Biodesix recorded a net loss of $7.8 million, highlighting ongoing financial challenges despite the positive revenue trajectory.

Apr 20, 2026

Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026

Biodesix, Inc. announced it will report its first quarter financial results for 2026 on May 4, 2026. The results will be released after trading hours, followed by a conference call at 4:30 p.m. ET for a business update. The company focuses on diagnostic solutions to enhance clinical care for patients.

Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis

Biodesix announced the publication of the largest clinical validation study for lung nodule biomarkers, supporting the Nodify CDT test's role in early lung cancer detection. The study demonstrated high specificity and consistent performance across various clinical settings, addressing a critical need in managing lung nodules. The findings are expected to enhance clinical decision-making and patient outcomes.

Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights

Biodesix, Inc. reported strong financial results for the fourth quarter and fiscal year 2025, including a 41% revenue increase to $28.8 million and an impressive gross margin of 83%. The company improved its net loss by 52%, recording its first positive Adjusted EBITDA of $0.5 million. For fiscal 2026, Biodesix anticipates revenue growth between $106 million and $112 million, showcasing optimism for continued profitability. The results reflect successful strategies in diagnostic testing and development services, strengthening Biodesix's position in the market.

Feb 24, 2026

Biodesix to Participate in Upcoming March 2026 Investor Conferences

Biodesix, Inc. has announced its participation in two upcoming investor conferences in March 2026. The management team will engage in fireside chats at the TD Cowen's 46th Annual Health Care Conference in Boston and the Barclays 28th Annual Global Healthcare Conference in Miami. These events aim to enhance investor relations and showcase the company's diagnostic solutions.

Feb 12, 2026

Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Biodesix, Inc. has announced the release of its financial results for Q4 and the full year of 2025, scheduled for February 26, 2026. The company will host a conference call and webcast at 4:30 p.m. ET to discuss these results and provide a business update. Interested parties can register for the webcast and participate in a Q&A session.

Jan 12, 2026